Glutamate Supplementation in Young Men

June 11, 2019 updated by: University of Waterloo

Glutamate Supplementation and Its Effects on Skeletal Muscle Glucose Metabolism During an Oral Glucose Challenge in Healthy Young Men

Amino acids play an important role in human metabolism. In aging individuals and in some diseases, certain amino acids, such as glutamate, are at lower than normal levels. Glutamate appears to be involved in providing energy and maintaining normal blood sugar (glucose) levels, processes which both depend heavily on skeletal muscle. The maintenance of healthy blood sugar levels, in particular, is tightly related to overall muscle mass and quality. To better understand the link between glutamate and glucose metabolism in skeletal muscle, the investigators will be using a nutritional approach to raise the body's glutamate levels with monosodium glutamate (MSG) supplementation, and raise blood glucose levels with a sugary drink. By altering the normal levels of glutamate and glucose in the blood and muscle tissue, the investigators can gather more information about the role of glutamate in energy metabolism. This will help the design of future studies investigating the function of glutamate in aging and disease. During this study the investigators will increase the levels of glutamate and glucose in the bloodstream by asking participants to ingest MSG along with a sugary drink. The goal is to subsequently determine: A) the amount of glutamate and glucose that ends up in the muscle; and B) whether normal skeletal muscle glucose metabolism, and the behaviour of additional amino acids (other than glutamate) is altered. The hypothesis is that when MSG and sugar drink are ingested together glucose uptake and metabolism within the skeletal muscle will be elevated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Glutamate is involved in several aspects of glucose metabolism in both muscle and liver, however its role has not been fully defined. It is the primary amino acid taken up by resting and exercising skeletal muscle, where it interacts with pyruvate (derived from glycolysis) to produce the TCA cycle intermediate 2-oxoglutarate and the gluconeogenic precursor alanine. Glutamate is also required for the production of glutamine, another gluconeogenic precursor, via intramuscular reactions with ammonia. Given that skeletal muscle is responsible for 85% of whole body glucose disposal, investigating the interplay between glutamate, its related amino acids, and glucose homeostasis is of particular relevance. However, despite its many links to energy provision, the role of glutamate in skeletal muscle glucose metabolism remains poorly understood.

Few studies have manipulated circulating concentrations of both glutamate and glucose in humans, and none have evaluated the effect of this unique manipulation in skeletal muscle tissue. In healthy young adults, a dose of roughly 10 g monosodium glutamate (MSG) transiently elevates plasma (700-800%) and intramuscular (30%) glutamate concentrations. Acute MSG supplementation also stimulates modest increases in plasma concentrations of aspartate, alanine, and glutamine (which are produced from glutamate within the muscle and subsequently released into circulation). Intriguingly, insulin is secreted in response to MSG supplementation, an effect that appears to be mediated by glutamate binding to an excitatory amino acid receptor on the pancreas. In addition to its action on the pancreas, there is some evidence to suggest that glutamate may function as a secondary messenger by enhancing glucose-stimulated insulin secretion during periods of increased carbohydrate (CHO) availability. However this secondary effect of glutamate on insulin is poorly understood.

The ability of glutamate to independently stimulate insulin secretion provides further support for an association between glutamate and glucose metabolism, yet only two studies to date have administered MSG during an oral glucose challenge to directly examine this relationship. One study observed no effect of MSG on glucose tolerance, however peak plasma glutamate was dramatically blunted in this study compared to previous reports (~ 80 vs. 400-500 µM), likely due to glutamate being retained in the gut as a result of co-ingestion with CHO. In a separate study, the authors developed a methodological approach to circumvent this issue: by staggering the administration of MSG and CHO by 30 min, plasma glutamate and glucose were both significantly and simultaneously elevated. Furthermore, MSG administration improved glucose tolerance. In support of these findings, improvements in glucose clearance following a high-fat meal combined with MSG has also been reported. Interestingly, not all studies have observed enhanced insulin secretion with higher glutamate availability. This suggests that the ability of carbohydrate to stimulate insulin secretion may overpower any effect of glutamate on this hormone, but the specific mechanisms remain to be fully elucidated.

Recently, investigators have developed a cell culture model to show that glutamate stimulates glucose uptake in rat L6 myotubes in the absence of insulin. This suggests that glutamate is capable of acting directly on skeletal muscle, and supports previous findings of improved glucose tolerance with acute MSG supplementation despite no further increase in insulin secretion. Additionally, cell data demonstrates that glutamate-stimulated glucose uptake results from increased glucose transporter 4 (GLUT4) translocation to the sarcolemma, via the activation of AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (MAPK). It is possible that these mechanisms underpin glutamate-mediated improvements in glucose tolerance in humans. However, this - as well as the fate of glucose upon being taken up by the muscle cell - has yet to be investigated.

There is a high degree of interplay between glutamate and glucose metabolism, but it remains unclear whether elevated plasma concentrations of glutamate and glucose influence one another's uptake into human skeletal muscle, as well as their subsequent respective intramuscular metabolic reactions. Therefore, the overarching goal of this study is to uncover the effects of acute MSG+CHO supplementation on plasma and intramuscular amino acid concentrations, as well as aspects of skeletal muscle glucose metabolism, in healthy young men in comparison to the ingestion of MSG and CHO alone.

The investigators will stagger the administration of MSG and CHO by 30 min to achieve simultaneous peak circulating concentrations of glutamate and glucose. Under these conditions, the aim is to:

Primary:

  1. Quantify and compare changes in circulating glutamate and intramuscular glutamate following MSG+CHO versus MSG alone.
  2. Evaluate the acute effects of MSG+CHO on the intramuscular free amino acid pool (specifically aspartate, alanine, and glutamine) compared with MSG adminstration alone.

Secondary:

  1. Confirm the findings of our previous study (7) which demonstrated that MSG+CHO attenuates the rise in plasma glucose (but does not affect insulin or C-peptide concentrations) compared with CHO alone.
  2. Determine if MSG+CHO is associated with a greater or lesser degree of signaling through the AMPK/p38 MAPK and/or insulin pathway in skeletal muscle compared to MSG and CHO alone.
  3. Explore whether aspects of skeletal muscle glucose uptake, storage, and/or utilization are altered during MSG+CHO, relative to CHO alone.

The investigators hypothesize that when glutamate and glucose are simultaneously available in peak concentrations in circulation they will observe:

Primary:

  1. Lower circulating and intramuscular glutamate concentrations following MSG+CHO versus MSG alone.
  2. Similar intramuscular concentrations of aspartate, alanine, and glutamine in response to MSG+CHO and MSG alone.

Secondary:

  1. A blunted increase in plasma glucose (but no difference in insulin or C-peptide concentrations) following MSG+CHO compared with CHO alone.
  2. Elevated expression and activation of proteins related to both AMPK/p38 MAPK and insulin signaling following MSG+CHO. However, AMPK/p38 MAPK signaling will be greatest following MSG alone, with negligible activation of the insulin signaling pathway. Conversely, insulin signaling will be greatest following CHO alone, with negligible signaling through AMPK/p38 MAPK.

Enhanced skeletal muscle glucose uptake (i.e. increased GLUT4 translocation to the plasma membrane) and utilization (i.e. increased rates of glycolysis and flux through the TCA cycle), compared to the administration of CHO alone.

Eligible young men who have consented to participate will visit the laboratory on 4 occasions each separated by a washout period of approximately 1 week. Following a series of baseline assessments to evaluate body composition, fitness etc.(Visit 1), participants will complete 3 trials (Visits 2, 3 and 4) in a randomized order. For each of the 3 trials, participants will arrive by car or via public transportation at the laboratory after an 8-12 hour overnight fast (no food or drink except for water after midnight the night before). A catheter will be inserted into an antecubital vein and a fasting blood sample will be drawn (~8 mL). Participants will then consume either 150 mg/kg body mass MSG or a placebo within 5 min. Blood (~8 mL) will be drawn at the following time points: 10, 20, 30, 40, 50, 60, 75, 90, 105, and 120 min. Immediately following the 30 min blood draw, participants will consume a 75 g carbohydrate (dextrose) beverage or a second placebo. After the last blood sample is obtained the catheter will be removed. The total amount of blood drawn during each trial will be ~88 mL.

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Waterloo, Ontario, Canada, N2L 3G1
        • University of Waterloo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 33 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • BMI in the normal or overweight range (18.5-30.0 kg/m2)
  • Weight stable for the past 6 months
  • Participate in aerobic and/or resistance-type exercise 3-5 times per week (no more then 2 hours per session and/or 5 sessions per week)
  • Fasting blood glucose < 6.0 mM
  • Resting blood pressure < 140/90 mmHg
  • Answer "no" to all questions on the Get Active Questionnaire (GAQ)

Exclusion Criteria:

  • Smoking
  • Known allergy or intolerance to MSG
  • Diabetes, cancer, or other metabolic disorders
  • Cardiac or gastrointestinal problems
  • Infectious disease
  • Injuries that prevent safe participation and exercise or instructions from healthcare provider to refrain from exercise
  • Barium swallow or nuclear medicine scan in the previous 3 weeks
  • If receiving a DXA scan will cause the participant to exceed the maximum trivial dose of radiation per year
  • Prescription anti-coagulant or anti-platelet medication (e.g. warfarin, heparin, clopiodogrel)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MSG + CHO
Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
Dietary supplement: MSG
150 mg/kg body mass monosodium glutamate (MSG).
Dietary supplement: CHO
75g CHO (i.e. dextrose)
Active Comparator: MSG + placebo B
Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
Dietary supplement: MSG
150 mg/kg body mass monosodium glutamate (MSG).
Dietary supplement: Placebo B
A non-caloric placebo composed of flavoured water.
Active Comparator: Placebo A + CHO
Participants will ingest placebo capsules followed by 75 g dextrose.
Dietary supplement: CHO
75g CHO (i.e. dextrose)
Dietary supplement: Placebo A
A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glutamate
Time Frame: ~ 2 hours post-ingestion
Circulating and intramuscular concentrations by HPLC
~ 2 hours post-ingestion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glucose
Time Frame: ~ 2 hours post-ingestion
Circulating concentrations using a spectrophotometric assay
~ 2 hours post-ingestion
Skeletal muscle glucose uptake
Time Frame: ~ 2 hours post-ingestion
As indicated by GLUT4 and laminin co-localization (immunohistochemistry)
~ 2 hours post-ingestion
Insulin
Time Frame: ~ 2 hours post-ingestion
Circulating concentrations using radioimmunoassay
~ 2 hours post-ingestion
C-peptide
Time Frame: ~ 2 hours post-ingestion
Circulating concentrations using radioimmunoassay
~ 2 hours post-ingestion
Aspartate
Time Frame: ~ 2 hours post-ingestion
Circulating and intramuscular concentrations by HPLC
~ 2 hours post-ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Waterloo

Investigators

  • Principal Investigator: Marina Mourtzakis, PhD, University of Waterloo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2018

Primary Completion (Actual)

October 2, 2018

Study Completion (Actual)

October 2, 2018

Study Registration Dates

First Submitted

January 17, 2018

First Submitted That Met QC Criteria

February 1, 2018

First Posted (Actual)

February 7, 2018

Study Record Updates

Last Update Posted (Actual)

June 12, 2019

Last Update Submitted That Met QC Criteria

June 11, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • ORE#: 22581

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on MSG

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe